Israel Prize in Life Sciences winner, and Weizmann Institute of Science researcher, Prof. Michal Schwartz, shares her journey of finding a way to cure Alzheimer's in the latest אחד ביום podcast.

Israel’s second-largest health service, Clalit Health Services, recently announced that it was including Curesponse’s AI driven technology, cResponse, into its oncology service package.

cResponse is an innovative platform that uniquely assesses how an individual patient's tumor tissue responds to a variety of cancer treatments. Clalit's decision will expand the access of this technology to millions of cancer patients, ultimately supporting the Curesponse mission to make cancer treatment selection truly personal.

Register today to secure your spot:

Congratulations to Prof. Nir London, winner of the Mark Foundation for Cancer 2023 Aspire Award.
The London lab develops and applies computational and experimental methods to design and discover new compounds for applications in chemical biology, drug discovery, and design, with a focus on covalent inhibition and kinase signaling.
Learn more about the London lab:

Yeda's spinoff company, UltraSight has announced that it has been granted a patent for real-time guidance of #ultrasound devices.

UltraLight is a #digitalhealth pioneer transforming cardiac imaging through the power of #AI. This technology aims to allow medical professionals with no prior sonography experience to accurately perform #echocardiographic examinations and acquire high quality diagnostic images of the #heart.

Read more:
 

Co-founded by eureKARE, an innovative European investment firm dedicated to building disruptive synthetic biology ventures and Yeda, EonBio is based on the groundbreaking research by Prof. Roy Bar-Ziv and his team at the Weizmann Institute of Science.
EonBio’s cutting-edge synthetic cell-free platform has the potential to revolutionize drug discovery, vaccine development, and bioproduction, empowering pharmaceutical companies to take on new challenges in their pursuit of more effective therapies.

For more information:
 

Did you know that heart disease is the leading cause of death worldwide, accounting for more deaths than all types of cancer combined? The impact it has on our society and healthcare system is staggering, with costs in the US alone reaching over $230 billion per year.

It's no secret that plants carry unique properties, for centuries plants have been used for a range of applications, including food, drugs and cosmetics.

But did you know that the benefits of plants can now be used without any interference to the plant itself?

The team led by Professor. Asaph Aharoni, from the Weizmann Institute of Science, has developed a method of inducing metabolite production in plants and extracting them without any harm being done.

Discover how in our latest newsletter:

Innovative biosynthesis technology company, Xinteza API, recently made a breakthrough discovery of a novel, non-cannabis plant-derived production system, capable of highly efficient and flawless end-to-end cannabinoid synthesis. This discovery is a major milestone in the path to uncover and exploit rare and new cannabinoid molecules with potentially novel pharmacological activities.

Xinteza is a spinoff company of Yeda, while leading the research is Professor Asaph Aharoni from the Weizmann Institute of Science.

The Kimchi Lab studies programmed cell death (PCD), an intricate molecular network governing a cell's decision to live or die. The lab aims to uncover new PCD targets and ultimately identify points of vulnerability in human disease amenable to therapeutic intervention.

Discover more about the research being done at the Kimchi Lab in our newsletter:

Israel's leading #QuantumComputing experts recently spoke in a panel during Calcalist כלכליסט Innovation Week. Amongst the speakers were Gil Semo from Quantum Source Labs Ltd and Dr. Ruti Ben Shlomi from LightSolver, two notable spinoffs of Yeda.

Learn more about the future of quantum computing:

Yes, you read that correctly, bugs.

With the world facing an unprecedented food crisis, the food-tech space has taken an interest in using bugs as an alternative source of protein. Bugs not only offer high nutritional value, they also produce fewer greenhouse gasses, emit less ammonia than farm animals and take up less space, water, and land than traditional sources of protein.

Decentralized low-cost emissions-free ammonia via electro catalytic reaction of water and air.

NitroFix, a spinoff company of Yeda, brings in a stable and scalable catalyst to an electrochemical process that can take place at room temperature, no heat and pressure needed.

Nitrofix allows on-site generation of ammonia for fertilizers and emerging use cases in fossil-free maritime fuels. Emissions-free ammonia is essential to decarbonize this legacy industry that burns 3% of the world’s natural gas.

IndieBio San Francisco - Batch 13 Demo Day is taking place tomorrow (January 19).

Join some of the top curated startups in climate tech, biotech and deep tech, including Yeda spinoff company NitroFix.

NitroFix was established based on research done at the laboratory of Professor Ronny Neumann from the Faculty of Chemistry at the Weizmann Institute of Science. It is the world's first proprietary electrolyzer that produces green ammonia directly from nitrogen and water, without the need for hydrogen.

Interested in learning more? Register online for free:

With no preventative therapy currently available for pre-leukemic individuals, that number is alarming. However, a group led by Professor Liran Shlush at the Weizmann Institute of Science has found that treatment with ROCK inhibitors can inhibit the growth of pre-leukemic mutated cells. This in turn, prevents disease onset.

This breakthrough could ultimately change the course of AML.

Discover more in our latest newsletter:

Looking back over the past 12 months, we can confidently say that 2022 was a successful year for Yeda. In the course of the past year, we have completed a series of important licensing deals for technologies that have emerged from all campus faculties, many of which have led to the formation of new entities.

Something exciting is happening in the world of Quantum Computing!

Last week, the Israel Innovation Authority announced the formation of the largest consortium in its history, with a three-year budget of NIS 115 million. Weizmann Institute of Science, professor Roee Ozeri is amongst the leading academic entities supporting the development.

AstraZeneca, Accenture, Amazon Web Services (AWS), and Clalit Health Services - the largest healthcare organization in Israel - have selected six startups to participate in BeyondBio SCALE. Among them is Yeda spinoff company, “Curesponse” - a unique, innovative and focused test combining tissue reactions to various drugs with rapid genomic sequencing for optimal cancer treatment adjustment.

Kadimastem, Spinoff company of Yeda, and iTolerance’s Proposed Collaboration Further Strengthened With Receipt of US $1 Million BIRD Foundation Grant

From left to right: Dr. Arik Hasson, Prof. Michel Revel, Anthony Japour, M.D., Mr. Asaf Shiloni, Dr. Kfir Molakandov

The food-tech industry is BUZZING with innovation, especially for this Yeda spinoff company called "FreezeM" - which recently raised €6.3M to help better position black soldier flies as an alternative protein source for animals and humans!

According to FreezeM CEO, Yuval Gilad, “The world is facing an unprecedented food crisis, with the global population expected to reach 10 billion people by 2050, thus new technologies are needed urgently to sustainably produce, store and transport animal protein feed.”

Happy Hanukah from Prof. Boris Rybtchinski and his team From Weizmann Institute, Yeda R&D and Ilan Sherman.

The beautiful " Chanukah menorah" was designed and sprayed by our creative consultant Ilan Sherman using the great technology of conductive spray developed in Prof. Boris Rybtchinski lab.

No more fuzzy photos! Have you ever zoomed in with your phone-camera only to discover poor, blurry or pixelated image quality? We’ve all been there. Fortunately, Prof. Michal Irani and her research team have developed an innovative Zero-shot Super-resolution (ZSSR) approach to help enhance camera zoom technology and achieve “crystal clarity” - without prior data training!

Good news for cardiac sonographers who are reliant on highly accurate, non-invasive cardiac imaging and transthoracic echocardiography solutions, thanks to a breakthrough in AI! Yeda’s spinoff company, UltraSight, was developed based on patented research conducted at the Weizmann Institute of Science in order to help streamline and optimize internal team processes as demonstrated in a recent landmark study.

When life gives you Carbon, make Carbonade! - With the global energy demand on the rise, mitigating CO2 emissions remains a major challenge for businesses everywhere. To reach a Net Zero goal, serious efforts are being made to help reduce new CO2 fossil-derived emissions.

AO and Liposphere Ltd. are proud to announce a joint program to make next-generation joint lubrication technology available to patients and physicians.

Founded in early 2019, Liposphere Ltd is a female-led biomedical Israeli start-up spun out via Yeda, based on research from the Department of Materials and Interfaces at the Weizmann Institute of Science.

The Company has developed a unique platform technology for water-based biolubricants to deliver ultra-low friction and efficient lubrication relevant to various medical and technological applications.

UltraSight is honored to receive this award and recognition. UltraSight look forward to a strong partnership with Bristol Myers Squibb on treating patients with cardiovascular disease

מלחמות בין נגיפים לחיידקים ניטשות כבר מאות מיליוני שנים. באחרונה חשפו מדעני מכון ויצמן למדע כיצד נגיפים מסוימים מתגברים על המערכת החיסונית של חיידקים, ופענחו את המבנה של מולקולה חיסונית חמקמקה המצויה בלב התהליך

כאן 11 | בן שני במסע בעקבות ההמצאות והחוקרים הישראליים שישנו את פני עולם הרפואה

פרק 2: סיפורם של החוקרים שמנסים לנצח את החיידקים העמידים לאנטיביוטיקה

להלן ציטוט של פרופ' רותם שורק ממכון ויצמן למדע

It's the battle of Food-coloring - Artificial vs. Real - which do you prefer? Thanks to some smart chemistry and a passion for food, Phytolon has stepped up to the plate! Rooted in research by Prof. Asaph Aharoni at the Department of Plant and Environmental Sciences at the Weizmann Institute of Science, we are pleased to see this Yeda spinoff company in C&EN's 10 Start-Ups to Watch!

We are pleased to announce that Metabolic Insights Ltd. Ltd, a subsidiary of YEDA, has signed an agreement with the RATION Consortium, which is funded by the EU Commission and is a member of the RATION Consortium.

RATION (stands for Risk AssessmenT InnOvatioN for low-risk pesticides) aims to propose an improved risk assessment for biological pesticides and will run for 4 years.

The Consortium includes the most prestigious universities across the EU and Israel and top tier agrochemical companies.

We are honored to announce that YEDA is participating and judging as this year's Silver Sponsors at the 10th anniversary of the AgriVest Conference in Tel Aviv, Nov. 8th, 2022!

Without further ado, feel free to learn more about this exciting event and the innovative projects to come out of it thanks to each team's involvement.

Bringing together hundreds of investors and multinational corporations with the most cutting-edge innovations, AgriVest 2022 is proud to keep the pulse of the #AgTech ecosystem in Israel!

With environmental concerns being at the forefront of the global consciousness, ClimateCrop Ltd. Ltd, a Yeda spinoff, is spearheading crop sustainability in agriculture and will be presenting at COP27.

There, attendees will discover how possible it is to increase crop yield and resilience in the face of future climate challenges, as well as reduce greenhouse gas emissions from our crops.

Be sure to visit their website to see how you can "Unleash the Potential of Every Plant!"

Sequentify collaborates with Yeda, the commercial arm of the Weizmann Institute of Science, under an NIH grant for evaluating the effect of clonal hematopoiesis on cognitive impairment and kidney function decline
 

When it comes to driving innovation, the numbers don't lie! 

In order to provide a holistic overview of the breadth and diversity of Our Work here at the Weizmann Institute of Science and Yeda, we are pleased to share our Facts and Figures for 2021 at a glance, along with our contact information. 

We encourage you to explore this beautifully illustrated scientific brochure to learn about all the things we do, from our patents to our people!

Depression is one of the most common psychiatric disorders, afflicting nearly 300 million people worldwide, with patients showing a heightened risk of self-harm and suicidal ideation.

A drug based on ketamine, a well-known anesthetic used in smaller doses as a party drug, was recently approved by the FDA and indicated for treatment-resistant depression. However, the drug’s use is still restricted, mainly due to the insufficiently understood mechanism of action.

BIO-Europe is here and we are excited to join this year! In attendance from YEDA will be Yael Klionsky, Elik Chapnik, and Ronen Kreizman, VP of Business Development Life Science.

From October 24–26, YEDA’s team will be on-site ready to meet, learn about new industry developments, and answer all your questions regarding YEDA's technologies which are currently available for license from the Weizmann Institute of Science.

Looking forward to seeing you there >> 

Israel’s ProFuse Technology raises $2.5M for technology that lowers the cost of cultured meat! With the rise of synthetically engineered food, cultured meat or "lab-grown" meat is one of the biggest breakthroughs in modern culinary science and technology. Unfortunately, high prices are impeding consumer mass adoption. Hoping to change that is Profuse Technology, a disruptive Yeda spin-off company, and is based on research done by Eldad Tzahor.

We are pleased to see Prof. Asaph Aharoni of the Weizmann Institute of Science recognized once more for his breakthrough research on cannabinoid biosynthesis production systems and collaboration with Yeda spinoff company, Xinteza API!

As cited in the report here, "This newly discovered gene pool includes a novel prenyl-transferase enzyme, featuring superior kinetics and improved flexibility in introduction into micro-organism-based expression systems."

Follow Xinteza API and continue reading to learn more >>
 

Diagnosing cancer is a complex process that may have just been simplified thanks to a new, multiparameter approach developed at the Weizmann Institute of Science, which may lead to a blood test that will diagnose cancer with unprecedented accuracy.

“Many of the conventional methods clinically available today to detect and diagnose cancer are invasive and unpleasant,” explains Dr. Efrat Shema of Weizmann’s Immunology and Regenerative Biology Department, who headed the research team.

The project partners Weizmann Institute of Science and Acceler8 Venture Builder have met in Rehovot - Israel to prepare the 3-year #EICTransition project funded by the #EU.

eBeam4Therapy aims to revolutionise #radiotherapy with a new approach based on very high energy electrons (VHEE), generated by laser plasma accelerators. This will provide better clinical outcomes and radically improve the quality of life of #cancer patients.

Phenol is an important industrial commodity, but the current production method has serious drawbacks related to safety, selectivity, and formation.

To address this issue, Prof. Ronny Neumann, Faculty of Chemistry, Molecular Chemistry and Materials Science at the Weizmann Institute of Science, recently developed a new phenol production method.

Based on electrocatalytic oxidation of benzene, the new production method is not only simple, efficient, and cost-effective, but it is a lot safer, too.

We are honored and delighted to share that The Weizmann Institute of Science is ranked number 8 on the Leiden global ranking (CWTS) of all scientific institutions and universities across the world.

YEDA continues to protect and commercialize innovations made possible only by scientists at Weizmann Institute of Science. Kudos!

Subdural hematoma (SDH) is a collection of blood between the inner layer of the dura and the brain that occurs mostly as a result of trauma. It is one of the most common neurosurgical conditions in the United States today. SDH monitoring for hematoma expansion would be beneficial to enable expeditious surgical intervention.

Congratulations to UltraSight, an Israeli-based digital health pioneer and Yeda spinoff, on obtaining a CE Mark for transforming cardiac imaging through the power of its ultrasound AI guidance software.
"UltraSight's technology allows medical professionals, regardless of their sonography experience, to successfully capture diagnostic quality ultrasound images of the heart."
Using Philips Lumify ultrasound device, UltraSight CE Mark was obtained following positive results from a clinical study at Sheba Medical Center, Israel, validating the technology and its effectiveness.

In a study to better understand how to treat inflammatory bowel disease at the Weizmann Institute of Science. Led by the group of Prof. Eran Elinav of the Systems Immunology Department, in collaboration with the Molecular Genetics Department’s Prof. Rotem Sorek and a Weizmann spinoff company - BiomX Inc., published their findings in the prestigious journal Cell.

Yeda spinoff, Xinteza API, has recently revealed a new source of cannabinoid biosynthesis that does not involve cannabinoids or cannabis. This breakthrough was discovered in research led by Professor Asaph Aharoni, Scientific Co-Founder of Xinteza and Head of the Weizmann Institute of Science Plant Metabolics Lab as well as Head of Weizmann’s Plant and Environmental Sciences Department.

“This discovery is a major milestone in the path to uncover and exploit rare and new cannabinoid molecules with potentially novel pharmacological activities”, says Aharoni.

ד"ר רותי בן שלומי וד"ר חן טרדונסקי עבדו באותו המסדרון במכון ויצמן והתעניינו באותה בעיה עד שהחליטו לשלב כוחות ולבנות מחשב על: "לייטסולבר" הוא מחשב אופטי מבוסס קרני לייזר והוא יכול לתרום לפתרון בעיות מסובכות בלוגיסטיקה, רפואה, בטחון ועוד. בן שלומי: "אנחנו לא המחשב האופטי הראשון בעולם אבל בכל המתחרים יש אלקטרוניקה, והיא הופכת לצוואר הבקבוק"

LightSolver is a spinoff of Yeda from the Weizmann Institute of Science

The Weizmann Institute managed to create a mouse embryo without fertilization and outside the uterus by challenging one of the most basic conditions of life. Hopefully, this breakthrough will open up a world of possibilities, from fertility problems to organs available for transplantation in the near future. Prof. Yaakov Hanna of the Weizmann Institute is our guest

A seed investment has been made in ClimateCrop - photosynthesis enhancement Ltd, a spinoff from Yeda, using state-of-the-art gene editing techniques to improve plant growth efficiency.

We are thrilled to announce the launch of Renewal Bio, a Yeda spinoff company leveraging breakthrough stem cell technologies from Prof. Jacob Hanna's lab, to drive therapeutic advancements in genetic diseases, infertility, longevity and other disease areas.

These are the spinouts that caught our eye over the past month. Here's why they should be on your radar, too.

Photomyne Ltd. is a Yeda - Technology Transfer Company of Weizmann Institute of Science portfolio company that leverages AI technology to empower families worldwide to scan, save and share their most precious photos and memories.

Scientists and entrepreneurs are increasingly turning to scent to help detect disease, boost memory, entertain, and protect people from food allergies.

The Nancy and Stephen Grand Israel National Center for Personalized Medicine at the Weizmann Institute is an advanced research facility that strives to promote the field of personalized medicine by providing Israeli academic, medical and biomedical industry researchers with access to state-of-the-art Genomics, Bioinformatics, Proteomics, High Throughput Screening and Medicinal Chemistry.

A brilliant solution has been developed by Weizmann Institute of Science professor, Yonina Eldar, and her team for Ultrasound Localization Microscopy (ULM) to aid in the early detection of microvascular changes, signaling diseases such as malignant tumors, inflammatory diseases, as well as myocardial and brain disorders.

Phytolon’s proprietary technology provides healthy, efficient, and sustainable natural food-coloring alternatives to azo/synthetic dyes used in food and beverages.

Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers

In the first half of 2022, Yeda has commercialized technologies from a broad range of disciplines at the Weizmann Institute, by partnering with existing companies as well as newly-established startups.

Three serial entrepreneurs and a leading Professor from the Weizmann Institute of Science join forces to establish Quantum Source and actualize a breakthrough technology that will enable photonic quantum computers that are 50,000x more efficient than state-of-the-art implementations.

Yeda spinoffs operate in a wide range of fields, from agriculture and plant genetics to diagnostics, nanotechnology and pharmaceuticals. Their activities, research and collaborations are often covered by the local and global press. The following is a small sample of publications that have recently featured innovative Yeda start-ups that leverage knowledge and technologies developed by the Weizmann Institute of Science.

Yeda is Coming to #BIO2022!

Come and meet Yeda at the upcoming BIO International Convention in San Diego! Elik Chapnik and Yael Klionsky will be presenting a wide range of our biopharma and diagnostic technologies.

Lysogene announced today that it has exercised its option to enter into an exclusive worldwide license agreement with Yeda Research and Development Co Ltd, the commercial arm of the Weizmann Institute of Science, for the development and commercialization of a gene therapy candidate for the treatment of neuronopathic Gaucher disease and Parkinson disease (PD) with GBA1 mutations.

The Weizmann Institute, in collaboration with Sheba Hospital, has developed a method that will allow a friendlier alternative to the invasive test: the detection of intestinal infections using cells that fall out of the intestinal mucosa and are excreted in the feces. Aside from the ability to diagnose Crohn’s or ulcerative colitis, the new method may also allow for customized treatments depending on the nature of the inflammation

Citrus fruits, delicious, healthy and full of Zionism, but also exposed to many hazards

Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders

The first edition of our newsletter is dedicated to some of our key highlights in 2021. The past year was a record year for licensing agreements. In addition, many potential deals were added to our pipeline, and we look forward to seeing many of them materialize in 2022.

The new company will be called Plantea Bioscience, and the researchers participating in the project are Prof. Sarel-Yaakov Fleischman from the Department of Biomolecular Sciences; Prof. Asaph Aharoni, Head of the Department of Plant and Environmental Sciences at the Institute; And Prof. Avraham A. Levy, Dean of the Faculty of Biochemistry at the Institute. Dr. Yaarit Weinberg, VP of the Impact NRS Group and the Company's Chief Operating Officer, will also be part of the team.

Over the past 6 months, approx. 800 followers have joined the page every month (see below). As of May 2021, the page has close to 5,500 followers, a majority of which hail from Israel and the United States. 28% of followers specialize in business development, while 13% are researchers. 29% hold senior-level positions in their respective organizations. This feat is even more impressive when examined from a business-size perspective. Out of 78,000 Israeli companies with a presence on LinkedIn, only 332 have over 5,000 followers.

BiomX: Rapidly Advancing Phage Therapeutics With Multiple Upcoming Catalysts. Yeda has licensed to BiomX a patent family with claims relating to "pharmaceutical composition and formulations, combinations of bacteriophage useful to treat acne, methods of use for these bacteriophage combinations, and methods of identifying patients who will respond to these bacteriophage combinations."

he Hunger Games: Uncovering the Secret of the Hunger Switch in the Brain. Why are some people always hungry, no matter how much they eat? Hadar Israeli, Dr. Moran Shalev-Benami and Dr. Oksana Degtjarik from the Weizmann Institute of Science's Chemical and Structural Biology Department have uncovered how the brain's master switch for hunger actually works. 

The clever addition of lipids to water-based hydrogels makes them excellent lubricants for biomedical uses. What copes with heavy pressure and exists in a state of constant friction, decade after decade, yet barely gets worn down? The answer is the cartilage padding our joints – actually a marvelous system that both absorbs shocks and lubricates the joints, allowing bones to slide easily against one another.

An interview with the CEO of Yeda, Dr. Opher Shapira, who took office in the midst of a pandemic and radical changes in the global economy

“The pioneering idea of Yeda Research and Development – to commercialize the ideas of the Institute’s scientists – was groundbreaking at the time, and it has proven itself over the years. Its major successes in pharmaceuticals have been impressive, but the world outside the academic one has changed greatly. That is why the Yeda model also needs to be updated.”

The new partnership between Impact NRS LLC, a leading company operating in the field of health, wellness and sustainable development innovation, and YEDA, the commercial arm of the Weizmann Institute of Science, has led to the establishment of Plantae Biosciences LTD, a company dedicated to developing food technology solutions that are geared to impact global nutrition and environmental security.

Top Influencers of Maariv - 25th Place (Hebrew)

A groundbreaking antibody treatment for Alzheimer’s disease developed by an Israeli scientist is currently headed toward a Phase I clinical trial. If successful, the treatment could become a game-changer for the disorder, modifying its course and preventing its progression.

Israeli natural food coloring developer Phytolon has announced that it has completed a $4.1 million financing round led by Millennium Food-Tech with the participation of Consensus Business Group (CBG) Fund, Trendlines Group, EIT-Food (the EU body responsible for food-tech initiatives), and former Elbit Systems CEO Yossi Ackerman. Phytolon's development is patent protected and belongs to Yeda, the technology transfer company of the Weizmann Institute of Science, which has granted Phytolon an exclusive license.

As the new CEO of EcoPhage, Orly Savion is writing a new and exciting chapter in her already-impressive professional career. She is also continuing her strong affiliation with the Weizmann Institute of Science and YEDA, the Institute's commercialization arm.

Pre-clinical studies suggest a protein, Agrin, could limit scarring and promote natural repair mechanisms after a heart attack

“The road from basic research to the clinic is long and often bumpy, so our study in pigs provides a critical step in this direction,” Tzahor says. This study was made possible, in part, by a new program that aims to bridge the gap between promising basic science breakthroughs at the Institute and commercial application. Called IDEA (Innovation, Development, Enhancement and Acceleration), it is an initiative of Yeda, Weizmann’s technology transfer arm.

Internal Differences: A New Method for Seeing into Cells

The new technology may help answer outstanding questions about the immune system, cancer, Alzheimer’s, and more.

The Weizmann scientists used their technology to address issues that have challenged researchers for years: the failure of the immune system to recognize and kill cancer cells and the failure of immunotherapy in treating most classifications of tumors.The group’s next step is to develop immunotherapy treatment using specific antibodies for clinical use and Amit is currently working with Yeda Research and Development - the technology transfer arm of the Weizmann Institute - to do so.

Phytolon has been selected by EIT Food to receive a share of €5.4 million in new funding.

The COVID-19 Bridge Fund supports #agrifood #startups at the forefront of European food innovation

Read more about the announcement here: https://lnkd.in/dbD9qjP

Phytolon (€393.6K, IL) uses an environmentally friendly fermentation-based technology to produce natural food colours that are GMO-free, high-quality and sustainable

DayTwo is a start-up that provides personalized nutrition recommendations, which help balance individual blood sugar levels. In the following article, DayTwo Co-Founder and CEO Lihi Segal discusses the importance of health-tech and how the company copes with the current pandemic crisis. She also recalls meeting Weizmann Institute researchers Prof. Eran Segal and Prof. Eran Elinav – whose groundbreaking research serves as the company's IP backbone – and talks about how the successful collaboration between industry and academic research has generated a sustainable win-win scenario.  

Lysogene has entered into a collaborative research agreement with Yeda Research and Development, a commercial branch of the Weizmann Institute of Science, to develop a gene therapy for neuronopathic Gaucher disease that affects the brain and spinal cord, the biopharmaceutical company announced.

The therapy also will be investigated as a treatment for Parkinson’s disease and other disorders caused by mutations in the GBA gene.

Weizmann Institute Recognized for High Performance by U-Multirank

U-Multirank, a leading European initiative that ranks universities worldwide based on a number of key performance parameters, has recognized the Weizmann Institute of Science as a 'Global Top-25 performer' in 2019, in two key categories: Top cited publications and the number of patents awarded. According to U-Multirank, the Weizmann Institute of Science is one of the top 25 universities in the world in both categories.

Prof Alon Harmelin and Dr. Slava Kalchenko, two Weizmann Institute scientists, developed TOVA – a innovative imaging system that can diagnose and monitor subdural hematomas frequently caused by head injuries. TOVA is a lightweight wearable headgear that connects to a mobile device, which will allow physicians to monitor their patients' conditions from afar. TOVA's groundbreaking technology includes infrared light and radiofrequency signals, coupled with a unique algorithm that was developed using an AI machine learning method. Together with neurologist Dr.

The Weizmann Institute and the Institute for Biological Research join hands to advance COVID-19 research.

The Coronavirus pandemic has prompted relevant responses from organizations from countless market and industry sectors – including scientific research institutions.

המרוץ אחר התרופה לקורונה: הצצה נדירה למעבדות של מכון וייצמן

מאז פרוץ מגפת הקורונה במכון ויצמן שברחובות מתנהלת מלחמה נגד הנגיף, במטרה למצוא כמה שיותר מהר חיסון או תרופה שתחזיר לציבור את החיים שהיו לפני המחלה. פגשנו שני פרופסורים מומחים, כל אחד בתחומו, שמספרים על תנאים לא קלים, חוסר בתקציב – אבל גם על פיתוחים משמעותיים שעד כה השיגו

תוצאות חיוביות.

A Stem of Support: PLX Stem Cells Provide COVID-19 Relief

Pluristem was founded in 2001 by Shai Meretzki of the Technion, who made use of a stem cell patent which was developed during his Ph.D studies, under the supervision of Dr. Shosh Merchav, together with Professors Dov Zipori and Avinoam Kadouri from the Weizmann Institute of Science

An Introduction to the Basic Complexities of Technology Transfer. Les Nouvelles, the journal of the Licensing Executives Society International (LES), recently published a fascinating article on the challenges of university technology transfer. One of the article's key contributors was YEDA's CEO Gil Granot-Mayer.

Ness Ziona, Israel – March 31, 2020: BiomX, a clinical stage company and a subsidiary of YEDA, the Weizmann Institute's technology transfer arm, recently announced that its positive Phase 1 data results would allow it to advance to a Phase 2 study. BiomX develops phage therapies that target specific pathogenic bacteria. These therapies include BX001, a topical gel comprised of naturally occurring phage that target C. acnes bacteria and aim to improve the appearance of acne-prone skin. The company's Phase 1 study exhibited a significant reduction of C.

An innovative Weizmann Institute initiative helps individuals track their sense of smell and potentially detect early signs of COVID-19.

The Coronavirus pandemic is forcing us all to confront the relative lack of anti-viral treatments that humanity has in its armamentarium. At the Weizmann Institute of Science, we confront this situation by harnessing innovative basic research for the development of novel technologies for the benefit of society. Together with Weizmann scientists, YEDA Ltd, the Institute's commercialization arm, is transforming academic research into drugs and public health technologies that may prevent future viral threats from causing upheaval similar to the disruption that our world is facing today.

On January 28th, Grove Ventures launched Frontier Tech, Israel's first “Deep Tech” conference. Yeda was a major partner in organizing this groundbreaking conference, helping Grove Ventures select its panel specialists, review content-related topics and execute various strategies.

Yeda, the Commercial Arm of the Weizmann Institute of Science, and Deerfield Create Orchard Innovations, LLC

Deerfield Commits up to $130 million to Advance New Medicines at the Israeli Institute Through a Newly Launched Company

Deerfield Commits up to $130 million to Advance New Medicines at Israeli Institute Through a Newly Launched Company

Yeda and Deerfield Create Orchard Innovations (Hebrew PR)

Bio-Leaders has agreed to commit $10 million towards a company being spun off of Yeda Research and Development, Weizmann’s technology transfer arm. Yongin, South Korea-headquartered biomedical company Bioleaders Corp. is looking at Israeli research institute The Weizmann Institute of Science for anti-cancer technology. BioLeaders has agreed to commit $10 million towards a company being spun off of Yeda Research and Development Co. Ltd., Weizmann’s technology transfer arm, the institute announced Tuesday.

The prestigious Leiden ranking puts the impact of Institute research high up in a list of the top universities and research institutes 08.07.2018

The Weizmann Institute of Science has been placed ninth in a ranking of research quality.  This is the second time that the Institute has ranked in the top ten best research institutes in the world. (In the previous ranking, in 2015, the institute placed tenth.) The placement comes from the annual CWTS Leiden Ranking, based in Leiden University in the Netherlands.

A protocol that arose from Weizmann Institute of Science research has led to US Food and Drug Administration approval of a new biological drug for the treatment of a certain form of lung cancer. This is the third cancer drug to be developed on the basis of studies conducted by the Weizmann Institute’s Prof. Michael Sela, of the Department of Immunology, and his colleagues.

Naiberg to head technology transfer at UCLA

A compound that disables cancer cells, an artificial cornea, the world’s first bone implant: 2017 saw major medical advances. We bring you the best

The Weizmann Institute of Science in Rehovot, Israel, and Yeda Research and Development Co., Ltd., its commercial arm, announced this week that they have entered a multi-year arrangement with Pfizer Inc. The arrangement will entail collaboration at the newly established National Drug Discovery Institute (DDI) in the Nancy and Stephen Grand Israel National Center for Personalized Medicine (G-INCPM), which is part of the Weizmann Institute and located on its campus.

Originally printed as an advertisement feature in Nature, Vol. 533, No. 7601 (5 May 2016)

One cannot predict what scientific discoveries or revolutions will be made in the laboratories of the Weizmann Institute of Science; but whatever they are, Yeda Research
and Development Co. will be there to bring them to market.

EAU TV spoke to Mark Emberton, UCL, and Eva Johannsen, University of Gothenburg at EAU16 about the use and limitations of active surveillance, how it affects quality of life, and a new drug that facilitates better prostate treatment.

Darmstadt, Germany, and Rehovot, Israel, February 16, 2016 – Merck, a leading science and technology company, announced that the Weizmann Institute conferred the renowned Weizmann Award in the Sciences and Humanities to Karl-Ludwig Kley, CEO and Chairman of the Executive Board and of Merck.

Darmstadt, Germany, and Rehovot, Israel, February 16, 2016 – Merck, a leading science and technology company, today extended the partnership with Weizmann Institute of Science, Rehovot, Israel, of by signing a new framework agreement, building on a successful innovation partnership of almost four decades.

Tel Aviv --   February 1,  2016:   NewCO2Fuels  (NCF), an Israeli start-up which transforms CO2 emissions into a clean fuel that can be sold as a commodity at competitive prices, was anno unced as the winner of the "Innovation Potential" category during the 2015 International Quality Inno vation of the Year Awards Ceremony this month in Tallinn, Estonia.

Weizmann Institute Drug, TOOKAD® Soluble, Approved for Prostate Cancer Therapy in Mexico

A therapy invented at the Weizmann Institute of Science and clinically developed in collaboration with Steba Biotech (Luxembourg) has been approved by Cofepris, Mexico’s health authority, for the focal treatment of early-stage prostate cancer.

Tech Republic, 2 December

http://www.techrepublic.com/article/how-new-fuel-tech-could-drastically-...

The stakes are high this week as world leaders convene in Paris for the United Nations Conference of Parties (COP21), intended to create a broad multilateral agreement limiting greenhouse gas emissions.

NCF’s technology, which captures CO2 emissions and turns them into fuel, may offer an alternative to cutting back on greenhouse gases

DAPHNE ROUSSEAU. 2015

The company called NewCO2Fuels, or NCF, has been developing its own version of a technology that allows heat-trapping carbon dioxide emissions to be captured and recycled back into useable fuel.

It sounds complicated — and it is — but the company’s founders say it holds real potential in the fight against global warming.

ImmunArray Ltd announces the Launch of the SLE-key™ Rule Out test to be run out of VERACIS the Company’s Service Laboratory beginning in March 2015, in Richmond, Virginia Richmond, VA and Rehovot, Israel. February 12, 2015 

XL-protein from Germany and Yeda, the commercial arm of the Weizmann Institute of Science, have announced the signing of a collaboration agreement for the commercial exploitation of an improved interferon molecule that was developed by scientists from the Institute and from XL-protein. The agreement states that Yeda will also represent the XL-protein scientists and may grant licenses to different companies for the development of applications of this molecule for the treatment of a line of diseases, including diseases of the central nervous system.

ALAMEDA, Calif.--(BUSINESS WIRE)--

3i to Develop Microscopes of the Future Based on Weizmann Institute Inventions

Yeda, the technology transfer arm of the Weizmann Institute of Science, has signed a license agreement with ’3i.’ Other microscopy systems based on Weizmann research are being sold by ‘Idea Bio-Medical’

REHOVOT, ISRAEL—July 25, 2012

An Israeli-Australian venture will use solar technology developed at the Weizmann Institute of Science to reduce carbon dioxide emissions from the burning of brown coal. The venture has been recently launched in Israel by NewCO2Fuels Ltd., a subsidiary of the Australian company Greenearth Energy Ltd., which has acquired an exclusive worldwide license for the solar technology from Yeda, the Weizmann Institute’s technology transfer arm.